Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Oncotype DX Genomic Prostate Score (GPS) Assay (Genomic Health Inc.) Lansdale: HAYES, Inc. Genetic Testing Publication. 2016 Authors' objectives Screening and treatment for prostate cancer is controversial and carries with it the potential for overdiagnosis and overtreatment, as many prostate cancers grow very slowly and affected men often die of other causes before prostate cancer becomes symptomatic. Therefore, in addition to the available risk stratification methods, there often remains uncertainty regarding the optimal treatment strategy for initial management of patients with localized prostate cancer. Additionally, the tumor tissue present in a needle biopsy specimen may not be accurately representative of the entire tumor, leading to the possibility of both overestimation and underestimation of risk for disease progression. Thus, a desire for increased precision in diagnosis and treatment recommendations has led to interest in evaluating biomarkers, allowing for a more personalized approach to management and treatment. The Oncotype DX Genomic Prostate Score (GPS) Assay is a tumor
gene expression profile test developed to assist treatment decisions for prostate cancer. This report examines the published evidence regarding the Oncotype DX GPS Assay. Indexing Status Subject indexing assigned by CRD MeSH Genomics; Humans; Prostate Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32017000086 Date abstract record published 06/01/2017 |